The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study).

Trial Profile

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms ICE
  • Sponsors Janssen Inc; Schering-Plough
  • Most Recent Events

    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2012 Actual initiation date changed from 1 Nov 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Planned End Date changed from 1 Nov 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top